Simple item page
 

The levels of adropin and its therapeutic potential in diabetes

cris.lastimport.scopus2025-10-23T06:57:31Z
cris.virtual.author-orcid0000-0003-4059-1362
cris.virtual.author-orcid0000-0002-3651-0972
cris.virtual.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtual.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtual.author-orcid0000-0002-1948-6544
cris.virtual.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtual.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtualsource.author-orcid9118c61a-b066-4efc-a7af-486f9ebf9021
cris.virtualsource.author-orcid652e209d-434a-47b3-b5fb-64c0aac5a84c
cris.virtualsource.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtualsource.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtualsource.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
cris.virtualsource.author-orcidb5ca3f7e-8c5b-47d7-b9c2-582f5ffa0e29
cris.virtualsource.author-orcid#PLACEHOLDER_PARENT_METADATA_VALUE#
dc.abstract.enAdropin, a peptide hormone encoded by the energy homeostasis-associated gene, is expressed in various tissues, including the brain. Accumulating evidence from in vivo and in vitro studies highlights adropin's pivotal role in modulating carbohydrate and lipid metabolism. Notably, circulating adropin levels are lower in overweight and obese humans, and experimental interventions involving adropin overexpression or synthetic administration demonstrate promising outcomes in mitigating obesity-related metabolic abnormalities and preventing weight gain. This review comprehensively summarizes the current understanding of adropin's potential implications in diverse types of diabetes. Specifically, it explores adropin's utility as a biomarker for different types of diabetes and elucidates its significance as a potential predictor of diabetic adverse outcomes. Furthermore, the review delves into the beneficial effects of adropin treatment in animal models of experimentally induced diabetes, shedding light on its mechanisms of action in modulating glucose metabolism. In this comprehensive overview, we aim to provide a nuanced understanding of multifaceted role of adropin in diabetes pathogenesis and its therapeutic potential in combating this global health challenge.
dc.affiliationWydział Medycyny Weterynaryjnej i Nauk o Zwierzętach
dc.affiliation.instituteKatedra Fizjologii, Biochemii i Biostruktury Zwierząt
dc.contributor.authorSkrzypski, Marek
dc.contributor.authorWojciechowicz, Tatiana
dc.contributor.authorRak, Agnieszka
dc.contributor.authorKrążek, Małgorzata
dc.contributor.authorFiedorowicz, Joanna
dc.contributor.authorStrowski, Mathias Z
dc.contributor.authorNowak, Krzysztof W.
dc.date.accessioned2025-05-08T11:30:09Z
dc.date.available2025-05-08T11:30:09Z
dc.date.issued2025
dc.description.abstract<jats:p>Adropin, a peptide hormone encoded by the energy homeostasis-associated gene, is expressed in various tissues, including the brain. Accumulating evidence from <jats:italic>in vivo</jats:italic> and <jats:italic>in vitro</jats:italic> studies highlights adropin's pivotal role in modulating carbohydrate and lipid metabolism. Notably, circulating adropin levels are lower in overweight and obese humans, and experimental interventions involving adropin overexpression or synthetic administration demonstrate promising outcomes in mitigating obesity-related metabolic abnormalities and preventing weight gain. This review comprehensively summarizes the current understanding of adropin's potential implications in diverse types of diabetes. Specifically, it explores adropin's utility as a biomarker for different types of diabetes and elucidates its significance as a potential predictor of diabetic adverse outcomes. Furthermore, the review delves into the beneficial effects of adropin treatment in animal models of experimentally induced diabetes, shedding light on its mechanisms of action in modulating glucose metabolism. In this comprehensive overview, we aim to provide a nuanced understanding of multifaceted role of adropin in diabetes pathogenesis and its therapeutic potential in combating this global health challenge.</jats:p>
dc.description.bibliographyil., bibliogr.
dc.description.financepublication_nocost
dc.description.financecost0,00
dc.description.if3,4
dc.description.number1
dc.description.points140
dc.description.volume265
dc.identifier.doi10.1530/JOE-24-0117
dc.identifier.eissn1479-6805
dc.identifier.issn0022-0795
dc.identifier.urihttps://sciencerep.up.poznan.pl/handle/item/2764
dc.languageen
dc.relation.ispartofJournal of Endocrinology
dc.relation.pagese240117
dc.rightsClosedAccess
dc.sciencecloudsend
dc.subject.enadropin
dc.subject.endiabetes
dc.subject.enenergy homeostasis associated gene
dc.subject.englucose
dc.subject.enGPR19
dc.subtypeReviewArticle
dc.titleThe levels of adropin and its therapeutic potential in diabetes
dc.typeJournalArticle
dspace.entity.typePublication
oaire.citation.issue1
oaire.citation.volume265